Two separate papers published in the New England Journal of Medicine showed that imetelstat demonstrated disease-modifying activities in phase II studies of myelofibrosis and essential thrombocythemia.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe